CD19 Targeting Therapies Approved by the FDA

Brand Name (Generic Drug Name)

Indications

Monjuvi (tafasitamab)¹

Treatment in combination with lenalidomide for adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible

for autologous stem cell transplant

Blincyto (blinatumomab)²

Treatment of adults and children with CD19-positive B-cell precursor ALL in first or second complete remission with MRD ≥0.1%

Treatment of adults and children with relapsed or refractory CD19-positive B-cell precursor ALL

Kymriah (tisagenlecleucel)³

Treatment of patients up to 25 years with B-cell precursor ALL that is refractory or in second or later relapse

Treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after 2 or more lines of systemic therapy, including DLBCL not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma

Treatment of adult patients with relapsed or refractory follicular lymphoma after

2 or more lines of systemic therapy

Yescarta (axicabtagene ciloleucel)⁴

Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy

Treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma

Treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy

Breyanzi (lisocabtagene maraleucel)⁵

Treatment of adult patients with large B-cell lymphoma, including DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy

Treatment of adult patients with large B-cell lymphoma, including DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation due to comorbidities or age

Treatment of adult patients with large B-cell lymphoma, including DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have relapsed or refractory disease after two or more lines of systemic therapy

CD19 Targeting Therapies in the Pipeline

Loncastuximab tesirine⁶

Treatment being evaluated in B-cell malignancies and Waldenström macroglobulinemia

TNB-486⁷

Treatment being evaluated in relapsed or refractory B-cell non-Hodgkin lymphoma